Amgen (AMGN) on Friday presented preliminary results from its first study on a cancer drug target called PRMT5 that selectively blocks the enzyme in cancer cells, showing five partial responses from 31 evaluable patients, STATnews’ Adam Feuerstein reports. Previously, a rival PRMT5 inhibitor being developed by Mirati Therapeutics (MRTX) factored into Bristol Myers Squibb’s (BMY) decision to acquire the company.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on AMGN: